New diagnostic strategy for sepsis-induced disseminated intravascular coagulation: a prospective single-center observational study

被引:45
作者
Ishikura, Hiroyasu [1 ]
Nishida, Takeshi [1 ]
Murai, Akira [1 ]
Nakamura, Yoshihiko [1 ]
Irie, Yuhei [1 ]
Tanaka, Junichi [1 ]
Umemura, Takehiro [1 ]
机构
[1] Fukuoka Univ, Dept Emergency & Crit Care Med, Fac Med, Jonan Ku, Fukuoka 8140180, Japan
关键词
CRITICALLY-ILL PATIENTS; INTENSIVE-CARE UNITS; ACTIVATED PROTEIN-C; INTERNATIONAL GUIDELINES; NATURAL-HISTORY; SEPTIC SHOCK; MULTICENTER; MANAGEMENT; PRESEPSIN; CRITERIA;
D O I
10.1186/cc13700
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Introduction: Inflammation and coagulation are closely interrelated pathophysiologic processes in the pathogenesis of sepsis. However, the diagnostic criteria of sepsis and disseminated intravascular coagulation (DIC) are different. This study aimed to define a biomarker panel to predict sepsis-induced DIC in emergency department patients. Methods: Eighty-two patients who were admitted to the emergency department of a tertiary university hospital were included in this study. The inclusion criteria were as follows: (1) age > 18 years; (2) >= 1 systemic inflammatory response syndrome (SIRS) criteria. Patients were excluded if they lacked biomarker data or apparent clinical manifestations. Eleven biomarkers were assayed from blood drawn on ED admission. Receiver operating curve (ROC) analysis including the area under the ROC and multivariable logistic regression were used to identify an optimal combination of biomarkers to create a diagnostic panel. The derived formula for weighting biomarker values was used to determine the severity of sepsis-induced DIC, which was divided into three categories: mild, moderate, and severe. We also investigated the ability of this classification to predict secondary outcome measures of rates of sepsis and DIC, DIC score, acute physiology and chronic health evaluation (APACHE) II score, sequential organ failure score (SOFA) score, and 28-day all-cause mortality. Results: Among the 11 biomarkers tested, the optimal 2-marker panel comprised presepsin and protein C. The area under the curve for the accuracies of predicting sepsis and DIC from these two biomarkers were 0.913 and 0.880, respectively. When patients were divided according to the severity of sepsis-induced DIC, all secondary outcomes except for mortality were significantly higher depending on the severity (P <.0001). The overall mortality rates of mild, moderate, and severe sepsis-induced DIC were 7.14%, 15.4%, and 28.6%, respectively (P =.0994). Conclusions: A biomarker panel of presepsin and protein C is predictive of the severity of sepsis-induced DIC in suspected ED patients. These criteria for sepsis-induced DIC are very simple, easy to implement, and can be used in intensive care units as a point-of-care test.
引用
收藏
页数:9
相关论文
共 51 条
  • [1] Promoting Global Research Excellence in Severe Sepsis (PROGRESS): Lessons from an International Sepsis Registry
    Beale, R.
    Reinhart, K.
    Brunkhorst, F. M.
    Dobb, G.
    Levy, M.
    Martin, G.
    Martin, C.
    Ramsey, G.
    Silva, E.
    Vallet, B.
    Vincent, J. -L.
    Janes, J. M.
    Sarwat, S.
    Williams, M. D.
    [J]. INFECTION, 2009, 37 (03) : 222 - 232
  • [2] Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis
    Bernard, GR
    Macias, WL
    Joyce, DE
    Williams, MD
    Bailey, J
    Vincent, JL
    [J]. CRITICAL CARE, 2003, 7 (02) : 155 - 163
  • [3] Efficacy and safety of recombinant human activated protein C for severe sepsis.
    Bernard, GR
    Vincent, JL
    Laterre, P
    LaRosa, SP
    Dhainaut, JF
    Lopez-Rodriguez, A
    Steingrub, JS
    Garber, GE
    Helterbrand, JD
    Ely, EW
    Fisher, CJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) : 699 - 709
  • [4] Recombinant human activated protein C (rhAPC) produces a trend toward improvement in morbidity and 28 day survival in patients with severe sepsis
    Bernard, GR
    Hartman, DL
    Helterbrand, JD
    Fisher, CJ
    [J]. CRITICAL CARE MEDICINE, 1999, 27 (01) : A33 - A33
  • [5] DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS
    BONE, RC
    BALK, RA
    CERRA, FB
    DELLINGER, RP
    FEIN, AM
    KNAUS, WA
    SCHEIN, RMH
    SIBBALD, WJ
    [J]. CHEST, 1992, 101 (06) : 1644 - 1655
  • [6] The immunopathogenesis of sepsis
    Cohen, J
    [J]. NATURE, 2002, 420 (6917) : 885 - 891
  • [7] Dellinger RP, 2013, INTENS CARE MED, V39, P165, DOI [10.1097/CCM.0b013e31827e83af, 10.1007/s00134-012-2769-8]
  • [8] Dellinger RP, 2008, INTENS CARE MED, V34, P783, DOI [10.1007/s00134-007-0934-2, 10.1007/s00134-008-1040-9, 10.1097/01.CCM.0000298158.12101.41]
  • [9] Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation
    Dhainaut, JF
    Yan, SB
    Joyce, DE
    Pettilä, V
    Basson, B
    Brandt, JT
    Sundin, DP
    Levi, M
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (11) : 1924 - 1933
  • [10] Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis
    Dhainaut, JF
    Yan, SB
    Cariou, A
    Mira, JP
    [J]. CRITICAL CARE MEDICINE, 2002, 30 (05) : S318 - S324